Preclinical studies have shown that blockade of the PD-1 pathway upregulates LAG-3 and combinatorial inhibition of LAG-3 and PD-1-PDL-1 axis in cancer exhibit durable antitumor response [48,49]. This evidence concerns the gene LAG3 and cancer.